Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

William J Gradishar

Showing results (71-80 of 195) with videos related to

Pageof 20
Sort By:
Clinical Breast Cancer|April 6, 2006
Plasma matrix metalloproteinases 7 and 9 in patients with metastatic breast cancer treated with marimastat or placebo: Eastern Cooperative Oncology Group trial E2196Stanley Zucker, Molin Wang, Joseph A Sparano, et al.
Journal of the National Cancer Institute|February 27, 2013
Author's reply to LamyJohn Hornberger, William J Gradishar, Michael D Alvarado, et al.
International Review of Cell and Molecular Biology|April 26, 2025
Circulation tumor cell isolation and enrichment technologiesYoubin Zhang, David Scholten, Wenan Qiang, et al.
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|July 16, 2024
Systemic Therapy in Breast CancerChiara Corti, Hemali Batra-Sharma, Max Kelsten, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 28, 2009
Significantly longer progression-free survival with nab-paclitaxel compared with docetaxel as first-line therapy for metastatic breast cancerWilliam J Gradishar, Dimitry Krasnojon, Sergey Cheporov, et al.
Future Oncology (London, England)|May 12, 2023
Margetuximab in HER2-positive metastatic breast cancerWilliam J Gradishar, Ruth O'Regan, Mothaffar F Rimawi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 21, 2005
Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancerWilliam J Gradishar, Sergei Tjulandin, Neville Davidson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 1, 2004
Randomized phase III trial of marimastat versus placebo in patients with metastatic breast cancer who have responding or stable disease after first-line chemotherapy: Eastern Cooperative Oncology Group trial E2196Joseph A Sparano, Patricia Bernardo, Patricia Stephenson, et al.
Breast Cancer Research and Treatment|October 18, 2020
The 21-gene recurrence score in node-positive, hormone receptor-positive, HER2-negative breast cancer: a cautionary tale from an NCDB analysisRoi Weiser, Waqar Haque, Efstathia Polychronopoulou, et al.
Breast Cancer Research and Treatment|May 2, 2012
A phase II trial of capecitabine in combination with the farnesyltransferase inhibitor tipifarnib in patients with anthracycline-treated and taxane-resistant metastatic breast cancer: an Eastern Cooperative Oncology Group Study (E1103)Tianhong Li, Mengye Guo, William J Gradishar, et al.
Pageof 20

Showing results (71-80 of 195) with videos related to

Sort By:
Pageof 20
Clinical Breast Cancer|April 6, 2006
Plasma matrix metalloproteinases 7 and 9 in patients with metastatic breast cancer treated with marimastat or placebo: Eastern Cooperative Oncology Group trial E2196Stanley Zucker, Molin Wang, Joseph A Sparano, et al.
Journal of the National Cancer Institute|February 27, 2013
Author's reply to LamyJohn Hornberger, William J Gradishar, Michael D Alvarado, et al.
International Review of Cell and Molecular Biology|April 26, 2025
Circulation tumor cell isolation and enrichment technologiesYoubin Zhang, David Scholten, Wenan Qiang, et al.
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|July 16, 2024
Systemic Therapy in Breast CancerChiara Corti, Hemali Batra-Sharma, Max Kelsten, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 28, 2009
Significantly longer progression-free survival with nab-paclitaxel compared with docetaxel as first-line therapy for metastatic breast cancerWilliam J Gradishar, Dimitry Krasnojon, Sergey Cheporov, et al.
Future Oncology (London, England)|May 12, 2023
Margetuximab in HER2-positive metastatic breast cancerWilliam J Gradishar, Ruth O'Regan, Mothaffar F Rimawi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 21, 2005
Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancerWilliam J Gradishar, Sergei Tjulandin, Neville Davidson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 1, 2004
Randomized phase III trial of marimastat versus placebo in patients with metastatic breast cancer who have responding or stable disease after first-line chemotherapy: Eastern Cooperative Oncology Group trial E2196Joseph A Sparano, Patricia Bernardo, Patricia Stephenson, et al.
Breast Cancer Research and Treatment|October 18, 2020
The 21-gene recurrence score in node-positive, hormone receptor-positive, HER2-negative breast cancer: a cautionary tale from an NCDB analysisRoi Weiser, Waqar Haque, Efstathia Polychronopoulou, et al.
Breast Cancer Research and Treatment|May 2, 2012
A phase II trial of capecitabine in combination with the farnesyltransferase inhibitor tipifarnib in patients with anthracycline-treated and taxane-resistant metastatic breast cancer: an Eastern Cooperative Oncology Group Study (E1103)Tianhong Li, Mengye Guo, William J Gradishar, et al.
Pageof 20